Global Leishmaniasis Treatment Market

Leishmaniasis Treatment Comprehensive Study by Application (Cutaneous leishmaniasis, Visceral leishmaniasis, Mucocutaneous leishmaniasis), Drug Type (Pentavalent antimonials (Sodium stibogluconate, SSG Meglumine antimoniate), Antibiotics (Amphotericin B, Liposomal amphotericin B, Miltefosine, Paromomycin, Pentamidine)), Distribution Channel (Clinics, Hospitals, Diagnostic Laboratory, Others), Test Type (Serological Tests, Parasitological Evaluation, DNA-based Methods, Immunological Methods, Others) Players and Region - Global Market Outlook to 2030

Leishmaniasis Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Leishmaniasis Treatment
Leishmaniasis is a parasitic disease caused by Leishmania parasite infection and spread by the bite of infected female phlebotomine sand flies. Mucocutaneous leishmaniasis, visceral leishmaniasis, and cutaneous leishmaniasis are the three types of leishmaniasis. Among the three types of leishmaniasis, visceral leishmaniasis (VL) is the most dangerous. Among the three types of leishmaniasis, visceral leishmaniasis (VL) is the most dangerous.The high prevalence of diseases in rural and developing countries, the rising prevalence of malnutrition globally, a lack of hygiene and poor sanitation facilities, population migratory patterns, the introduction of new chemical entities in the field of therapeutics, favourable government regulations, and increased R&D investments are all expected to fuel the global leishmaniasis tr market's growth.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Leishmaniasis Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Sanofi S.A. (France), Sequus Pharmaceuticals Inc. (United States), Paladin Labs Inc. (Canada), Drugs for Neglected Diseases Initiative (Switzerland), Gilead Life sciences (United States), Enzon Pharmaceuticals Inc. (United States), Gland Pharma Limited (India), Mirum Pharmaceuticals (United States), Lifecare Innovations Private Limited (India) and Novartis (Switzerland) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Leishmaniasis Treatment market by , Application (Cutaneous leishmaniasis, Visceral leishmaniasis and Mucocutaneous leishmaniasis) and Region.



On the basis of geography, the market of Leishmaniasis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Type, the sub-segment i.e. Pentavalent antimonials (Sodium stibogluconate, SSG Meglumine antimoniate) will boost the Leishmaniasis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Clinics will boost the Leishmaniasis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Test Type, the sub-segment i.e. Serological Tests will boost the Leishmaniasis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased Awareness About the Availability of Different Therapies

Market Growth Drivers:
Increased Incidents of Leishmaniasis Disease Across the world and Rising Prevalence of Unhealthy Lifestyles

Challenges:
Lack of R&D in the Treatment of Leishmaniasis

Restraints:
Lack of Awareness Among People

Opportunities:
Increasing Number of FDA Approvals and Continuous Research and Development in Scientific Technology to Cure this Disease

February 2020 – Novartis and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world's leading parasitic killers.


Key Target Audience
Drug Companies, Medical Device Companies, Investors, Medical Research Companies and Governmental Bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Cutaneous leishmaniasis
  • Visceral leishmaniasis
  • Mucocutaneous leishmaniasis
By Drug Type
  • Pentavalent antimonials (Sodium stibogluconate, SSG Meglumine antimoniate)
  • Antibiotics (Amphotericin B, Liposomal amphotericin B, Miltefosine, Paromomycin, Pentamidine)

By Distribution Channel
  • Clinics
  • Hospitals
  • Diagnostic Laboratory
  • Others

By Test Type
  • Serological Tests
  • Parasitological Evaluation
  • DNA-based Methods
  • Immunological Methods
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Incidents of Leishmaniasis Disease Across the world
      • 3.2.2. Rising Prevalence of Unhealthy Lifestyles
    • 3.3. Market Challenges
      • 3.3.1. Lack of R&D in the Treatment of Leishmaniasis
    • 3.4. Market Trends
      • 3.4.1. Increased Awareness About the Availability of Different Therapies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Leishmaniasis Treatment, by Application, Drug Type, Distribution Channel, Test Type and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Leishmaniasis Treatment (Value)
      • 5.2.1. Global Leishmaniasis Treatment by: Application (Value)
        • 5.2.1.1. Cutaneous leishmaniasis
        • 5.2.1.2. Visceral leishmaniasis
        • 5.2.1.3. Mucocutaneous leishmaniasis
      • 5.2.2. Global Leishmaniasis Treatment by: Drug Type (Value)
        • 5.2.2.1. Pentavalent antimonials (Sodium stibogluconate, SSG Meglumine antimoniate)
        • 5.2.2.2. Antibiotics (Amphotericin B, Liposomal amphotericin B, Miltefosine, Paromomycin, Pentamidine)
      • 5.2.3. Global Leishmaniasis Treatment by: Distribution Channel (Value)
        • 5.2.3.1. Clinics
        • 5.2.3.2. Hospitals
        • 5.2.3.3. Diagnostic Laboratory
        • 5.2.3.4. Others
      • 5.2.4. Global Leishmaniasis Treatment by: Test Type (Value)
        • 5.2.4.1. Serological Tests
        • 5.2.4.2. Parasitological Evaluation
        • 5.2.4.3. DNA-based Methods
        • 5.2.4.4. Immunological Methods
        • 5.2.4.5. Others
      • 5.2.5. Global Leishmaniasis Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Leishmaniasis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi S.A. (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sequus Pharmaceuticals Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Paladin Labs Inc. (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Drugs for Neglected Diseases Initiative (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Gilead Life sciences (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Enzon Pharmaceuticals Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Gland Pharma Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mirum Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lifecare Innovations Private Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Leishmaniasis Treatment Sale, by Application, Drug Type, Distribution Channel, Test Type and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Leishmaniasis Treatment (Value)
      • 7.2.1. Global Leishmaniasis Treatment by: Application (Value)
        • 7.2.1.1. Cutaneous leishmaniasis
        • 7.2.1.2. Visceral leishmaniasis
        • 7.2.1.3. Mucocutaneous leishmaniasis
      • 7.2.2. Global Leishmaniasis Treatment by: Drug Type (Value)
        • 7.2.2.1. Pentavalent antimonials (Sodium stibogluconate, SSG Meglumine antimoniate)
        • 7.2.2.2. Antibiotics (Amphotericin B, Liposomal amphotericin B, Miltefosine, Paromomycin, Pentamidine)
      • 7.2.3. Global Leishmaniasis Treatment by: Distribution Channel (Value)
        • 7.2.3.1. Clinics
        • 7.2.3.2. Hospitals
        • 7.2.3.3. Diagnostic Laboratory
        • 7.2.3.4. Others
      • 7.2.4. Global Leishmaniasis Treatment by: Test Type (Value)
        • 7.2.4.1. Serological Tests
        • 7.2.4.2. Parasitological Evaluation
        • 7.2.4.3. DNA-based Methods
        • 7.2.4.4. Immunological Methods
        • 7.2.4.5. Others
      • 7.2.5. Global Leishmaniasis Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Leishmaniasis Treatment: by Application(USD Million)
  • Table 2. Leishmaniasis Treatment Cutaneous leishmaniasis , by Region USD Million (2018-2023)
  • Table 3. Leishmaniasis Treatment Visceral leishmaniasis , by Region USD Million (2018-2023)
  • Table 4. Leishmaniasis Treatment Mucocutaneous leishmaniasis , by Region USD Million (2018-2023)
  • Table 5. Leishmaniasis Treatment: by Drug Type(USD Million)
  • Table 6. Leishmaniasis Treatment Pentavalent antimonials (Sodium stibogluconate, SSG Meglumine antimoniate) , by Region USD Million (2018-2023)
  • Table 7. Leishmaniasis Treatment Antibiotics (Amphotericin B, Liposomal amphotericin B, Miltefosine, Paromomycin, Pentamidine) , by Region USD Million (2018-2023)
  • Table 8. Leishmaniasis Treatment: by Distribution Channel(USD Million)
  • Table 9. Leishmaniasis Treatment Clinics , by Region USD Million (2018-2023)
  • Table 10. Leishmaniasis Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 11. Leishmaniasis Treatment Diagnostic Laboratory , by Region USD Million (2018-2023)
  • Table 12. Leishmaniasis Treatment Others , by Region USD Million (2018-2023)
  • Table 13. Leishmaniasis Treatment: by Test Type(USD Million)
  • Table 14. Leishmaniasis Treatment Serological Tests , by Region USD Million (2018-2023)
  • Table 15. Leishmaniasis Treatment Parasitological Evaluation , by Region USD Million (2018-2023)
  • Table 16. Leishmaniasis Treatment DNA-based Methods , by Region USD Million (2018-2023)
  • Table 17. Leishmaniasis Treatment Immunological Methods , by Region USD Million (2018-2023)
  • Table 18. Leishmaniasis Treatment Others , by Region USD Million (2018-2023)
  • Table 19. South America Leishmaniasis Treatment, by Country USD Million (2018-2023)
  • Table 20. South America Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 21. South America Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 22. South America Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 23. South America Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 24. Brazil Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 25. Brazil Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 26. Brazil Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 27. Brazil Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 28. Argentina Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 29. Argentina Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 30. Argentina Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 31. Argentina Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 32. Rest of South America Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 33. Rest of South America Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 34. Rest of South America Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 35. Rest of South America Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 36. Asia Pacific Leishmaniasis Treatment, by Country USD Million (2018-2023)
  • Table 37. Asia Pacific Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 38. Asia Pacific Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 39. Asia Pacific Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 40. Asia Pacific Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 41. China Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 42. China Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 43. China Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 44. China Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 45. Japan Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 46. Japan Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 47. Japan Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 48. Japan Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 49. India Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 50. India Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 51. India Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 52. India Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 53. South Korea Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 54. South Korea Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 55. South Korea Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 56. South Korea Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 57. Taiwan Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 58. Taiwan Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 59. Taiwan Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 60. Taiwan Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 61. Australia Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 62. Australia Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 63. Australia Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 64. Australia Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 69. Europe Leishmaniasis Treatment, by Country USD Million (2018-2023)
  • Table 70. Europe Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 71. Europe Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 72. Europe Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 73. Europe Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 74. Germany Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 75. Germany Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 76. Germany Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 77. Germany Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 78. France Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 79. France Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 80. France Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 81. France Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 82. Italy Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 83. Italy Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 84. Italy Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 85. Italy Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 86. United Kingdom Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 87. United Kingdom Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 88. United Kingdom Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 89. United Kingdom Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 90. Netherlands Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 91. Netherlands Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 92. Netherlands Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 93. Netherlands Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 94. Rest of Europe Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 95. Rest of Europe Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 96. Rest of Europe Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 97. Rest of Europe Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 98. MEA Leishmaniasis Treatment, by Country USD Million (2018-2023)
  • Table 99. MEA Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 100. MEA Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 101. MEA Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 102. MEA Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 103. Middle East Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 104. Middle East Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 105. Middle East Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 106. Middle East Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 107. Africa Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 108. Africa Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 109. Africa Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 110. Africa Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 111. North America Leishmaniasis Treatment, by Country USD Million (2018-2023)
  • Table 112. North America Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 113. North America Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 114. North America Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 115. North America Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 116. United States Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 117. United States Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 118. United States Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 119. United States Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 120. Canada Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 121. Canada Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 122. Canada Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 123. Canada Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 124. Mexico Leishmaniasis Treatment, by Application USD Million (2018-2023)
  • Table 125. Mexico Leishmaniasis Treatment, by Drug Type USD Million (2018-2023)
  • Table 126. Mexico Leishmaniasis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 127. Mexico Leishmaniasis Treatment, by Test Type USD Million (2018-2023)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Leishmaniasis Treatment: by Application(USD Million)
  • Table 139. Leishmaniasis Treatment Cutaneous leishmaniasis , by Region USD Million (2025-2030)
  • Table 140. Leishmaniasis Treatment Visceral leishmaniasis , by Region USD Million (2025-2030)
  • Table 141. Leishmaniasis Treatment Mucocutaneous leishmaniasis , by Region USD Million (2025-2030)
  • Table 142. Leishmaniasis Treatment: by Drug Type(USD Million)
  • Table 143. Leishmaniasis Treatment Pentavalent antimonials (Sodium stibogluconate, SSG Meglumine antimoniate) , by Region USD Million (2025-2030)
  • Table 144. Leishmaniasis Treatment Antibiotics (Amphotericin B, Liposomal amphotericin B, Miltefosine, Paromomycin, Pentamidine) , by Region USD Million (2025-2030)
  • Table 145. Leishmaniasis Treatment: by Distribution Channel(USD Million)
  • Table 146. Leishmaniasis Treatment Clinics , by Region USD Million (2025-2030)
  • Table 147. Leishmaniasis Treatment Hospitals , by Region USD Million (2025-2030)
  • Table 148. Leishmaniasis Treatment Diagnostic Laboratory , by Region USD Million (2025-2030)
  • Table 149. Leishmaniasis Treatment Others , by Region USD Million (2025-2030)
  • Table 150. Leishmaniasis Treatment: by Test Type(USD Million)
  • Table 151. Leishmaniasis Treatment Serological Tests , by Region USD Million (2025-2030)
  • Table 152. Leishmaniasis Treatment Parasitological Evaluation , by Region USD Million (2025-2030)
  • Table 153. Leishmaniasis Treatment DNA-based Methods , by Region USD Million (2025-2030)
  • Table 154. Leishmaniasis Treatment Immunological Methods , by Region USD Million (2025-2030)
  • Table 155. Leishmaniasis Treatment Others , by Region USD Million (2025-2030)
  • Table 156. South America Leishmaniasis Treatment, by Country USD Million (2025-2030)
  • Table 157. South America Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 158. South America Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 159. South America Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 160. South America Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 161. Brazil Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 162. Brazil Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 163. Brazil Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 164. Brazil Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 165. Argentina Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 166. Argentina Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 167. Argentina Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 168. Argentina Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 169. Rest of South America Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 170. Rest of South America Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 171. Rest of South America Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 172. Rest of South America Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 173. Asia Pacific Leishmaniasis Treatment, by Country USD Million (2025-2030)
  • Table 174. Asia Pacific Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 175. Asia Pacific Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 176. Asia Pacific Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 177. Asia Pacific Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 178. China Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 179. China Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 180. China Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 181. China Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 182. Japan Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 183. Japan Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 184. Japan Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 185. Japan Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 186. India Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 187. India Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 188. India Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 189. India Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 190. South Korea Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 191. South Korea Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 192. South Korea Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 193. South Korea Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 194. Taiwan Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 195. Taiwan Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 196. Taiwan Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 197. Taiwan Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 198. Australia Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 199. Australia Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 200. Australia Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 201. Australia Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 206. Europe Leishmaniasis Treatment, by Country USD Million (2025-2030)
  • Table 207. Europe Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 208. Europe Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 209. Europe Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 210. Europe Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 211. Germany Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 212. Germany Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 213. Germany Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 214. Germany Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 215. France Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 216. France Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 217. France Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 218. France Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 219. Italy Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 220. Italy Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 221. Italy Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 222. Italy Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 223. United Kingdom Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 224. United Kingdom Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 225. United Kingdom Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 226. United Kingdom Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 227. Netherlands Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 228. Netherlands Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 229. Netherlands Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 230. Netherlands Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 231. Rest of Europe Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 232. Rest of Europe Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 233. Rest of Europe Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 234. Rest of Europe Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 235. MEA Leishmaniasis Treatment, by Country USD Million (2025-2030)
  • Table 236. MEA Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 237. MEA Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 238. MEA Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 239. MEA Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 240. Middle East Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 241. Middle East Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 242. Middle East Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 243. Middle East Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 244. Africa Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 245. Africa Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 246. Africa Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 247. Africa Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 248. North America Leishmaniasis Treatment, by Country USD Million (2025-2030)
  • Table 249. North America Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 250. North America Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 251. North America Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 252. North America Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 253. United States Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 254. United States Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 255. United States Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 256. United States Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 257. Canada Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 258. Canada Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 259. Canada Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 260. Canada Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 261. Mexico Leishmaniasis Treatment, by Application USD Million (2025-2030)
  • Table 262. Mexico Leishmaniasis Treatment, by Drug Type USD Million (2025-2030)
  • Table 263. Mexico Leishmaniasis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 264. Mexico Leishmaniasis Treatment, by Test Type USD Million (2025-2030)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Leishmaniasis Treatment: by Application USD Million (2018-2023)
  • Figure 5. Global Leishmaniasis Treatment: by Drug Type USD Million (2018-2023)
  • Figure 6. Global Leishmaniasis Treatment: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Leishmaniasis Treatment: by Test Type USD Million (2018-2023)
  • Figure 8. South America Leishmaniasis Treatment Share (%), by Country
  • Figure 9. Asia Pacific Leishmaniasis Treatment Share (%), by Country
  • Figure 10. Europe Leishmaniasis Treatment Share (%), by Country
  • Figure 11. MEA Leishmaniasis Treatment Share (%), by Country
  • Figure 12. North America Leishmaniasis Treatment Share (%), by Country
  • Figure 13. Global Leishmaniasis Treatment share by Players 2023 (%)
  • Figure 14. Global Leishmaniasis Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global Leishmaniasis Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 18. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 19. Sequus Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Sequus Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Paladin Labs Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 22. Paladin Labs Inc. (Canada) Revenue: by Geography 2023
  • Figure 23. Drugs for Neglected Diseases Initiative (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Drugs for Neglected Diseases Initiative (Switzerland) Revenue: by Geography 2023
  • Figure 25. Gilead Life sciences (United States) Revenue, Net Income and Gross profit
  • Figure 26. Gilead Life sciences (United States) Revenue: by Geography 2023
  • Figure 27. Enzon Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Enzon Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Gland Pharma Limited (India) Revenue, Net Income and Gross profit
  • Figure 30. Gland Pharma Limited (India) Revenue: by Geography 2023
  • Figure 31. Mirum Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 32. Mirum Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 33. Lifecare Innovations Private Limited (India) Revenue, Net Income and Gross profit
  • Figure 34. Lifecare Innovations Private Limited (India) Revenue: by Geography 2023
  • Figure 35. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 37. Global Leishmaniasis Treatment: by Application USD Million (2025-2030)
  • Figure 38. Global Leishmaniasis Treatment: by Drug Type USD Million (2025-2030)
  • Figure 39. Global Leishmaniasis Treatment: by Distribution Channel USD Million (2025-2030)
  • Figure 40. Global Leishmaniasis Treatment: by Test Type USD Million (2025-2030)
  • Figure 41. South America Leishmaniasis Treatment Share (%), by Country
  • Figure 42. Asia Pacific Leishmaniasis Treatment Share (%), by Country
  • Figure 43. Europe Leishmaniasis Treatment Share (%), by Country
  • Figure 44. MEA Leishmaniasis Treatment Share (%), by Country
  • Figure 45. North America Leishmaniasis Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sanofi S.A. (France)
  • Sequus Pharmaceuticals Inc. (United States)
  • Paladin Labs Inc. (Canada)
  • Drugs for Neglected Diseases Initiative (Switzerland)
  • Gilead Life sciences (United States)
  • Enzon Pharmaceuticals Inc. (United States)
  • Gland Pharma Limited (India)
  • Mirum Pharmaceuticals (United States)
  • Lifecare Innovations Private Limited (India)
  • Novartis (Switzerland)
Select User Access Type

Key Highlights of Report


Apr 2024 243 Pages 60 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Leishmaniasis Treatment Market Quantitative research analysis
Global Leishmaniasis Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Sanofi S.A. (France), Sequus Pharmaceuticals Inc. (United States), Paladin Labs Inc. (Canada), Drugs for Neglected Diseases Initiative (Switzerland), Gilead Life sciences (United States), Enzon Pharmaceuticals Inc. (United States), Gland Pharma Limited (India), Mirum Pharmaceuticals (United States), Lifecare Innovations Private Limited (India) and Novartis (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increased Awareness About the Availability of Different Therapies" is seen as one of major influencing trends for Leishmaniasis Treatment Market during projected period 2023-2030.
The Leishmaniasis Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Leishmaniasis Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Phage Therapy Comprehensive Study by Application (Diagnostic, Antimicrobial Drug Discovery, Veterinary Medicines, Others), Route of Administration (Oral, Topical), Targeted Bacteria (Escherichia coli...
$ 3750
Respiratory Virus Infection Drugs Comprehensive Study by Type (Penicillin VK, Amoxicillin, Penicillin G benzathine, Cefadroxil, Erythromycin, Amoxicillin and clavulanate, Others), Disease Type (COVID...
$ 3750
Behcet's Disease Treatment Comprehensive Study by Type (Anti-inflammatory Medications (Ibuprofen), Topical Ointments (Corticosteroid), Immunosuppressive Medications), Route of Administration (Oral, I...
$ 3750
Wolff Parkinson White Syndrome Treatment Comprehensive Study by Type (Type A, Type B), Treatment (Drugs {Anti-Arrhythmic, Beta-Blockers, Others}, Cardioversion, Radiofrequency Catheter Ablation, Surg...
$ 3750
Transurethral Resection of the Prostate (TURP) Comprehensive Study by Application (Hospital, Clinic, Laboratory), Devices (Resectoscopes, Catheters and Resectoscopes Electrodes, Monopolar Electrodes...
$ 3650
Amifostine Market Comprehensive Study by Application (Ovarian Cancer Adjuvant Therapy, Head and Neck Cancer Adjuvant Therapy, Others), Distribution Channel (Online, Offline), Type of Drug (Tablet, Ca...
$ 3450